A detailed history of Profund Advisors LLC transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Profund Advisors LLC holds 24,858 shares of DNLI stock, worth $613,495. This represents 0.03% of its overall portfolio holdings.

Number of Shares
24,858
Previous 29,373 15.37%
Holding current value
$613,495
Previous $682,000 6.16%
% of portfolio
0.03%
Previous 0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$20.96 - $31.05 $94,634 - $140,190
-4,515 Reduced 15.37%
24,858 $724,000
Q2 2024

Aug 13, 2024

SELL
$14.96 - $23.22 $584,950 - $907,925
-39,101 Reduced 57.1%
29,373 $682,000
Q1 2024

May 08, 2024

BUY
$15.83 - $23.35 $234,268 - $345,556
14,799 Added 27.57%
68,474 $1.41 Million
Q4 2023

Feb 14, 2024

BUY
$16.2 - $23.18 $219,040 - $313,416
13,521 Added 33.67%
53,675 $1.15 Million
Q3 2023

Nov 13, 2023

SELL
$20.63 - $30.17 $130,402 - $190,704
-6,321 Reduced 13.6%
40,154 $828,000
Q2 2023

Aug 10, 2023

SELL
$23.37 - $32.96 $54,966 - $77,521
-2,352 Reduced 4.82%
46,475 $1.37 Million
Q1 2023

May 11, 2023

BUY
$21.91 - $32.67 $744,063 - $1.11 Million
33,960 Added 228.43%
48,827 $1.12 Million
Q4 2022

Feb 02, 2023

BUY
$26.28 - $33.92 $50,063 - $64,617
1,905 Added 14.7%
14,867 $413,000
Q3 2022

Nov 04, 2022

BUY
$25.97 - $38.53 $4,830 - $7,166
186 Added 1.46%
12,962 $398,000
Q2 2022

Aug 01, 2022

SELL
$20.88 - $35.19 $30,860 - $52,010
-1,478 Reduced 10.37%
12,776 $376,000
Q1 2022

May 10, 2022

SELL
$29.0 - $47.27 $45,994 - $74,970
-1,586 Reduced 10.01%
14,254 $459,000
Q4 2021

Feb 08, 2022

SELL
$42.59 - $55.02 $77,215 - $99,751
-1,813 Reduced 10.27%
15,840 $706,000
Q3 2021

Nov 12, 2021

BUY
$48.48 - $78.23 $726,327 - $1.17 Million
14,982 Added 560.91%
17,653 $891,000
Q2 2021

Aug 12, 2021

BUY
$50.3 - $78.44 $134,351 - $209,513
2,671 New
2,671 $210,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.31B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Profund Advisors LLC Portfolio

Follow Profund Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Profund Advisors LLC with notifications on news.